Abdul-Rahim AH, et al. - In this retrospective analysis of the Digitalis Investigation Group (DIG) trial, digoxin's impacts were assessed in patients with the newly described phenotype of heart failure (HF) and mid-range ejection fraction (HFmrEF), ascribed to mild left ventricular systolic dysfunction. Based on left ventricular ejection fraction (LVEF) category, three mutually exclusive groups of patients were formed: <40% (HF with reduced LVEF, HFrEF), 40–49% (HFmrEF) and ≥50% (HF with preserved LVEF, HFpEF). Patients in these groups were given digoxin or placebo and their outcomes were compared. Event rates in patients with HFmrEF were found to be closer to those in HFpEF than HFrEF. The greatest effect of digoxin on HF hospitalization was seen in patients with HFrEF, while an intermediate effect and the smallest effect was observed in HFmrEF and HFpEF, respectively.